Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study

Autor: Magda A.-A. El-Sayed, Esam R. Ahmed, Walaa M. El-Husseiny, Alaa A.-M. Abdel-Aziz, Adel S. El-Azab, Naglaa I. Abdel-Aziz
Rok vydání: 2018
Předmět:
Models
Molecular

Antioxidant
Stereochemistry
medicine.medical_treatment
Antineoplastic Agents
Pyrazoline
antioxidant effect
01 natural sciences
Antioxidants
HeLa
α
β-Unsaturated ketone

Structure-Activity Relationship
chemistry.chemical_compound
Heterocyclic Compounds
Cell Line
Tumor

Drug Discovery
medicine
Humans
Structure–activity relationship
EGFR inhibition
Protein Kinase Inhibitors
IC50
Cell Proliferation
Pharmacology
Dose-Response Relationship
Drug

Molecular Structure
biology
010405 organic chemistry
Cell growth
lcsh:RM1-950
General Medicine
molecular docking
Ketones
biology.organism_classification
In vitro
0104 chemical sciences
ErbB Receptors
010404 medicinal & biomolecular chemistry
lcsh:Therapeutics. Pharmacology
chemistry
Pyran
Drug Screening Assays
Antitumor

antitumour activity
Research Paper
Zdroj: Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 33, Iss 1, Pp 507-518 (2018)
Journal of Enzyme Inhibition and Medicinal Chemistry
DOI: 10.6084/m9.figshare.5900878
Popis: New α,β-unsaturated ketones 4a,b; 5a–c; and 6a,b; as well as 4-H pyran 7; pyrazoline 8a,b; isoxazoline 9; pyridine 10–11; and quinoline-4-carboxylic acid 12a,b derivatives were synthesized and evaluated for in vitro antitumour activity against HepG2, MCF-7, HeLa, and PC-3 cancer cell lines. Antioxidant activity was investigated by the ability of these compounds to scavenge the 2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) radical cation (ABTS•+). Compounds 6a, 6b, 7, and 8b exhibited potent antitumour activities against all tested cell lines with [IC50] ≅5.5–18.1 µΜ), in addition to significantly high ABTS•+ scavenging activities. In vitro EGFR kinase assay for 6a, 6b, 7, and 8b as the most potent antitumour compounds showed that; compounds 6b, and 7 exhibited worthy EGFR inhibition activity with IC50 values of 0.56 and 1.6 µM, respectively, while compounds 6a and 8b showed good inhibition activity with IC50 values of 4.66 and 2.16 µM, respectively, compared with sorafenib reference drug (IC50 = 1.28 µM). Molecular modelling studies for compounds 6b, 7, and 8b were conducted to exhibit the binding mode towards EGFR kinase, which showed similar interaction with erlotinib.
Databáze: OpenAIRE